ERBB2 and breast cancer: DRAIC was also investigated in the Oncomine database and very intriguingly, we found its high expression may indicate resistance to paclitaxel and FEC while on the contrary, sensitivity to lapatinib, which inhibits HER2 and is widely used as anti-HER2 therapy in HER2 overexpressing breast cancer patients.